companies abbvie-inc 
Law 360
AUGUST 1, 2024
AbbVie Inc. says it's still owed nearly $1 million by a Massachusetts biopharmaceutical company for materials and work it provided as the smaller firm prepared to seek U.S. Food and Drug Administration approval of a potential cancer treatment, according to a lawsuit filed in state court.
Law 360
JANUARY 8, 2024
A shareholder alleges that ImmunoGen Inc. directors and advisers significantly undervalued the company while preparing to sell to AbbVie Inc., including by failing to consider the $1.6 billion in projected revenue from a new ovarian cancer drug, according to a suit filed Monday.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Law 360
DECEMBER 17, 2024
A pension fund investor in Cerevel Therapeutics Holdings Inc. has sued Bain Capital Investors LLC and other alleged insiders of the company in Delaware's Court of Chancery, accusing them of lining up a secondary offering in the biopharmaceutical venture before disclosure of its planned sale to AbbVie.
Patently O
APRIL 15, 2021
Oracle America, Inc., Argument Pending : One final case is set to be argued this term: Minerva Surgical, Inc. Hologic, Inc., In this case, the employee started his own competing company and was sued for patent infringement. Kingston Technology Company, Inc., 20-271; Rovi Guides, Inc. Iancu , No.
Law 360
MAY 18, 2022
AbbVie Inc. executives have been hit with a new suit over allegations the company illegally marketed its drug Humira, this time from an investor who says the company's top brass prioritized "profit over compliance and market dominance over safety" and ultimately cost shareholders when it all came to light.
Law 360
SEPTEMBER 22, 2021
is liable to distributor AbbVie Endocrine Inc. for breaching their supply agreement for cancer drug Lupron Depot, a Delaware Chancery judge ruled Wednesday, teeing the companies up for a second trial to determine the damages stemming from ongoing delivery disruptions. Japanese drugmaker Takeda Pharmaceutical Co.
FDA Law Blog
SEPTEMBER 17, 2024
By Sarah Wicks & Dara Katcher Levy — FDA’s Office of Prescription Drug Promotion (OPDP) has issued its fourth Untitled Letter of 2024 – this one to AbbVie, Inc. The Untitled Letter also references OPDP advisory comments previously provided to the prior holder of the UBRELVY New Drug Application (NDA) (Allergan, Inc.)
Expert insights. Personalized for you.
98 
Let's personalize your content